The Aurora Kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme

Pei Ying Lee, Chi Long Chen, Zhong Zhe Lin, Ann Lii Cheng, Edmund I Tsuen Chen, Jacqueline Whang-Peng, Chi Ying F Huang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is one of the most common and aggressive types of primary brain tumor. After complete surgical resection combined with radiation and chemotherapy, approximately 10% of patients survive for more than 5 years. Therefore, a novel therapy for GBM is needed. Aurora-A (AURKA) plays important roles in cell cycle regulation, such as centrosome maturation, chromatic separation, bipolar spindle assembly, and mitotic entry. To investigate the effects of AURKA inhibition, three GBM cell lines, including GBM 8401, GBM 8901, and U87-MG cells, were treated with the AURKA inhibitor VE-465. Sensitivities to VE-465, as indicated by 50% inhibitory concentration values for GBM 8401, GBM 8901, and U87-MG cells, were 6, 25, and 19 nM, respectively. Additionally, colony formation of GBM 8401 and GBM 8901 cells was decreased after treatment with the VE-465. VE-465 treatment increased polyploidy and p53 protein expression, and inhibited cell growth in a caspase-independent manner. Taken together, these results suggest that the inhibition of AURKA by a small-molecule inhibitor may have potential to serve as a novel therapeutic approach for GBM.

Original languageEnglish
Pages (from-to)326-335
Number of pages10
JournalOncology
Volume84
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Aurora Kinases
Glioblastoma
Aurora Kinase A
Therapeutics
VX680
Centrosome
Spindle Apparatus
Polyploidy
Caspases
Brain Neoplasms
Inhibitory Concentration 50
Cell Cycle
Color

Keywords

  • Brain tumor
  • Glioblastoma multiforme
  • VE-465

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The Aurora Kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme. / Lee, Pei Ying; Chen, Chi Long; Lin, Zhong Zhe; Cheng, Ann Lii; Chen, Edmund I Tsuen; Whang-Peng, Jacqueline; Huang, Chi Ying F.

In: Oncology, Vol. 84, No. 6, 06.2013, p. 326-335.

Research output: Contribution to journalArticle

Lee, Pei Ying ; Chen, Chi Long ; Lin, Zhong Zhe ; Cheng, Ann Lii ; Chen, Edmund I Tsuen ; Whang-Peng, Jacqueline ; Huang, Chi Ying F. / The Aurora Kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme. In: Oncology. 2013 ; Vol. 84, No. 6. pp. 326-335.
@article{eccf4f99f555411f98c5817ceb033464,
title = "The Aurora Kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme",
abstract = "Glioblastoma multiforme (GBM) is one of the most common and aggressive types of primary brain tumor. After complete surgical resection combined with radiation and chemotherapy, approximately 10{\%} of patients survive for more than 5 years. Therefore, a novel therapy for GBM is needed. Aurora-A (AURKA) plays important roles in cell cycle regulation, such as centrosome maturation, chromatic separation, bipolar spindle assembly, and mitotic entry. To investigate the effects of AURKA inhibition, three GBM cell lines, including GBM 8401, GBM 8901, and U87-MG cells, were treated with the AURKA inhibitor VE-465. Sensitivities to VE-465, as indicated by 50{\%} inhibitory concentration values for GBM 8401, GBM 8901, and U87-MG cells, were 6, 25, and 19 nM, respectively. Additionally, colony formation of GBM 8401 and GBM 8901 cells was decreased after treatment with the VE-465. VE-465 treatment increased polyploidy and p53 protein expression, and inhibited cell growth in a caspase-independent manner. Taken together, these results suggest that the inhibition of AURKA by a small-molecule inhibitor may have potential to serve as a novel therapeutic approach for GBM.",
keywords = "Brain tumor, Glioblastoma multiforme, VE-465",
author = "Lee, {Pei Ying} and Chen, {Chi Long} and Lin, {Zhong Zhe} and Cheng, {Ann Lii} and Chen, {Edmund I Tsuen} and Jacqueline Whang-Peng and Huang, {Chi Ying F}",
year = "2013",
month = "6",
doi = "10.1159/000347021",
language = "English",
volume = "84",
pages = "326--335",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "6",

}

TY - JOUR

T1 - The Aurora Kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme

AU - Lee, Pei Ying

AU - Chen, Chi Long

AU - Lin, Zhong Zhe

AU - Cheng, Ann Lii

AU - Chen, Edmund I Tsuen

AU - Whang-Peng, Jacqueline

AU - Huang, Chi Ying F

PY - 2013/6

Y1 - 2013/6

N2 - Glioblastoma multiforme (GBM) is one of the most common and aggressive types of primary brain tumor. After complete surgical resection combined with radiation and chemotherapy, approximately 10% of patients survive for more than 5 years. Therefore, a novel therapy for GBM is needed. Aurora-A (AURKA) plays important roles in cell cycle regulation, such as centrosome maturation, chromatic separation, bipolar spindle assembly, and mitotic entry. To investigate the effects of AURKA inhibition, three GBM cell lines, including GBM 8401, GBM 8901, and U87-MG cells, were treated with the AURKA inhibitor VE-465. Sensitivities to VE-465, as indicated by 50% inhibitory concentration values for GBM 8401, GBM 8901, and U87-MG cells, were 6, 25, and 19 nM, respectively. Additionally, colony formation of GBM 8401 and GBM 8901 cells was decreased after treatment with the VE-465. VE-465 treatment increased polyploidy and p53 protein expression, and inhibited cell growth in a caspase-independent manner. Taken together, these results suggest that the inhibition of AURKA by a small-molecule inhibitor may have potential to serve as a novel therapeutic approach for GBM.

AB - Glioblastoma multiforme (GBM) is one of the most common and aggressive types of primary brain tumor. After complete surgical resection combined with radiation and chemotherapy, approximately 10% of patients survive for more than 5 years. Therefore, a novel therapy for GBM is needed. Aurora-A (AURKA) plays important roles in cell cycle regulation, such as centrosome maturation, chromatic separation, bipolar spindle assembly, and mitotic entry. To investigate the effects of AURKA inhibition, three GBM cell lines, including GBM 8401, GBM 8901, and U87-MG cells, were treated with the AURKA inhibitor VE-465. Sensitivities to VE-465, as indicated by 50% inhibitory concentration values for GBM 8401, GBM 8901, and U87-MG cells, were 6, 25, and 19 nM, respectively. Additionally, colony formation of GBM 8401 and GBM 8901 cells was decreased after treatment with the VE-465. VE-465 treatment increased polyploidy and p53 protein expression, and inhibited cell growth in a caspase-independent manner. Taken together, these results suggest that the inhibition of AURKA by a small-molecule inhibitor may have potential to serve as a novel therapeutic approach for GBM.

KW - Brain tumor

KW - Glioblastoma multiforme

KW - VE-465

UR - http://www.scopus.com/inward/record.url?scp=84876800051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876800051&partnerID=8YFLogxK

U2 - 10.1159/000347021

DO - 10.1159/000347021

M3 - Article

C2 - 23636005

AN - SCOPUS:84876800051

VL - 84

SP - 326

EP - 335

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 6

ER -